TOKEN2049
8.7.2022 10:45:13 CEST | Business Wire | Press release
TOKEN2049 , Asia’s premier crypto conference, has announced a new batch of title sponsors and speakers for its upcoming Singapore edition which will be running from 28 to 29 September. This year marks the conference’s Singapore debut, making for a thrilling week of activities as some of the world’s most pioneering projects gather at what’s set to be the crypto industry’s first major in-person event in Asia ahead of the Formula 1 Singapore Grand Prix 2022 race weekend.
In recognition of growing excitement around the event, TOKEN2049 Singapore’s roster of sponsors grew to 200 firms within the last three weeks. New additions to its line-up of title sponsors include next-generation crypto spot and derivatives trading exchange OKX ; leading hardware wallet manufacturer Ledger ; one of the world’s largest crypto exchanges Kucoin ; Hong Kong-based digital asset exchange AAX ; the world’s largest cryptocurrency derivatives copy trade platform Bitget ; and homegrown Singaporean crypto exchange Coinhako, which secured its major payment institution license earlier this year.
A notable addition to this year's Title Sponsor lineup is a leading South Korean game company WEMADE , best known as the creator of leading MMORPG series Legend of Mir which sees over 120 million players worldwide. WEMADE has been servicing blockchain games since 2020, and currently 14 titles are onboarded on its platform WEMIX , including MIR4, the number 1 play-to-earn MMORPG.
A WEMADE spokesperson said: “With the industry growing at unprecedented levels and the amount of innovation it’s channeling globally, TOKEN2049 and the important conversations that it will catalyse couldn’t have come at a better time.”
As the flagship event of Asia Crypto Week , the conference is expected to draw 3,000 attendees from across the world. This year’s impressive line-up includes Stani Kulechov, Founder and CEO of AAVE, the leading open-source and non-custodial liquidity protocol; Haseeb Kureshi, Managing Partner of Dragonfly Capital; and Eli Ben-Sasson, Co-Founder and President of Starkware and co-inventor of zkSTARK, the privacy-preserving cryptographic proof.
Panels and keynotes at the event are set to address a broad agenda — from the evolving regulatory landscape and institutional investment trends to the rise of the metaverse, Web3, and what this will ultimately mean for the industry as mainstream awareness intensifies.
The Singapore event is set to be the largest in TOKEN2049’s history amid the token economy’s huge potential to transform industries and communities around the world. As a testament to growing interest among broader mainstream audiences, McLaren Racing Formula One driver Daniel Ricciardo, the new brand ambassador for world-leading crypto trading app and web3 platform OKX, will also be speaking at the conference ahead of Sunday’s Singapore Grand Prix 2022 race, sharing his views on digital assets and the evolving nature of fan engagement.
Additional speakers at this year’s conference include Justin Sun, Founder of Tron, the open-source, Proof-of-Stake blockchain platform and Sandeep Nailwal, Co-Founder of Polygon, the decentralised Ethereum scaling platform.
Commenting on the 200-sponsor milestone, Raphael Strauch, Founder of TOKEN2049 said: “The numbers don’t lie, and this overwhelming interest and energy only bode well for the industry. I’m thrilled to see the conversations and solutions that will emerge from Singapore this September.”
As part of Asia Crypto Week, attendees can expect to attend a full line-up of side events, including Pantera Blockchain Summit Asia, Milken Institute Asia Summit, and Algorand AVM Singapore, with many more to be announced in the coming weeks.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom